Author + information
- Received February 3, 2009
- Revision received May 26, 2009
- Accepted June 18, 2009
- Published online November 3, 2009.
- Justin M.S. Lee, MB, BCh⁎,
- Matthew D. Robson, PhD⁎,
- Ly-Mee Yu, MSc†,
- Cheerag C. Shirodaria, MD⁎,
- Colin Cunnington, MBBS⁎,
- Ilias Kylintireas, MD⁎,
- Janet E. Digby, PhD⁎,
- Thomas Bannister, BA⁎,
- Ashok Handa, MB, BS‡,
- Frank Wiesmann, MD⁎,
- Paul N. Durrington, MD§,
- Keith M. Channon, MD⁎,
- Stefan Neubauer, MD⁎ and
- Robin P. Choudhury, DM⁎,⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Robin P. Choudhury, Department of Cardiovascular Medicine, Level 6, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, United Kingdom
Objectives Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function.
Background NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density lipoprotein cholesterol and is widely used as an adjunct to statin therapy in patients with coronary artery disease. Although changes in plasma lipoproteins suggest potential benefit, there is limited evidence of the effects of NA on disease progression when added to contemporary statin treatment.
Methods We performed a double-blind, randomized, placebo-controlled study of 2 g daily modified-release NA added to statin therapy in 71 patients with low HDL-C (<40 mg/dl) and either: 1) type 2 diabetes with coronary heart disease; or 2) carotid/peripheral atherosclerosis. The primary end point was the change in carotid artery wall area, quantified by magnetic resonance imaging, after 1 year.
Results NA increased HDL-C by 23% and decreased low-density lipoprotein cholesterol by 19%. At 12 months, NA significantly reduced carotid wall area compared with placebo (adjusted treatment difference: −1.64 mm2[95% confidence interval: −3.12 to −0.16]; p = 0.03). Mean change in carotid wall area was −1.1 ± 2.6 mm2for NA versus +1.2 ± 3.0 mm2for placebo. In both the treatment and placebo groups, larger plaques were more prone to changes in size (r = 0.4, p = 0.04 for placebo, and r = −0.5, p = 0.02 for NA).
Conclusions In statin-treated patients with low HDL-C, high-dose modified-release NA, compared with placebo, significantly reduces carotid atherosclerosis within 12 months. (Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function; NCT00232531)
This was an investigator-initiated study funded by Merck KGaA. The study sponsor was the University of Oxford. Data were analyzed and the manuscript prepared by the investigators without input from Merck. Dr. Choudhury has received research grants from Merck and GlaxoSmithKline, and has received speaker's or consultancy fees from Merck, AstraZeneca, Sanofi, and Solvay. Dr. Choudhury's laboratory is funded by the Wellcome Trust, and supported by the Oxford Comprehensive Biomedical Research Centre, National Institute for Health Research funding scheme.
- Received February 3, 2009.
- Revision received May 26, 2009.
- Accepted June 18, 2009.
- American College of Cardiology Foundation